US Patent 11957666 Regimen for suppressing organ rejection
Patent 11957666 was granted and assigned to Veloxis Pharmaceuticals on April, 2024 by the United States Patent and Trademark Office.
All edits
Edits on 17 Apr, 2024
Golden AI
Edits made to:
Infobox (+18 properties)
Article (+492 characters)
US Patent 11957666 Regimen for suppressing organ rejection
Article
Patent abstract
The present invention relates to a method of suppressing organ rejection in a patient receiving an organ transplant by initiating oral treatment with a once-daily extended release tacrolimus dosage form, for example, at an initial dose of from about 0.15 to about 0.20 mg/kg/day within 24 or 48 hours following transplantation. The once-daily extended release tacrolimus dosage form (i) provides low fluctuation and/or swing of tacrolimus, (ii) provides a significantly lower C
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
William J. Polvino0
Date of Patent
April 16, 2024
0Patent Application Number
174475810
Date Filed
September 14, 2021
0Patent Citations
Patent Primary Examiner
CPC Code
Find more entities like US Patent 11957666 Regimen for suppressing organ rejection
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.